A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 9223
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : MDS
Long Form : myelodysplastic syndrome
No. Year Title Co-occurring Abbreviation
2023 A Late and Complex Presentation of Hereditary Haemochromatosis. HH, RAEB
2023 A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. aGVHD, allo-HSCT, AML, CR, DLI, OS, PR, RFS, TRM
2023 Acute Myeloid Leukemia in a Patient With Human Immunodeficiency Virus-Related High-Risk Myelodysplastic Syndrome. AIDS, AML, HIV
2023 Advances in myelodysplastic syndromes: promising novel agents and combination strategies. HMA
2023 Analysis of Immune-Cell Distribution of Bone Marrow in Patients with Myelodysplastic Syndrome. IPSS-R
2023 Case report: Venetoclax therapy in a boy with acute myeloid leukemia in Shwachman Diamond syndrome. AML, HSCT, SDS
2023 Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. allo-HSCT, AML, R/R
2023 Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience. AML
2023 Clinical significance of prognostic nutritional index in myelodysplastic syndrome. OS, PFS, PNI
10  2023 Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification. AML, ICC
11  2023 Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS registry study. EQ-5D-3L, GEE, HRQoL, OR, VAS
12  2023 Diagnosis of immune pathophysiology in patients with bone marrow failure. AA, aAA, BM, HSCs
13  2023 Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in BRAF and p.R461* in NF1 Genes-A Case Report with Literature Review. PD-L1, SqCC
14  2023 Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes. CMP, GMP, HSC, HSPC, MEP, NBM, rhEPO, ROS, RS
15  2023 Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept. AML, ESA, MDS-RS, MPGN, TGF-beta
16  2023 Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF). AEL, AML, LSC, MRD, PEL
17  2023 Mesenchymal stromal cell senescence in haematological malignancies. AML, BM, BM-MSCs, CLL, MBL, MGUS, MM, SASP
18  2023 Myelodysplastic syndromes, thy name is heterogeneity. ICC
19  2023 Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases. MPN
20  2023 On behalf of the SFGM-TC: prophylactic donor lymphocyte infusion in patients treated with allogeneic stem-cell transplantation for high-risk myelodysplastic syndrome and acute myeloid leukemia. allo-HSCT, AML, DLI, proDLI
21  2023 Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. ---
22  2023 Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome. ---
23  2023 T-replete cord transplants give superior outcomes in high risk and relapsed/refractory paediatric myeloid malignancy. AML, EFS, GVHD, HR, MRD, OS, R/R, SCT, TRM
24  2023 The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. AML, MFC, MMD, NGS, PCR
25  2023 The value of serum IL-4 to predict the survival of MDS patients. CD, IL, OS
26  2023 Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world. CI, ESA, HMA, OS
27  2023 Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single cell resolution. GRN, HSPCs, scRNA-seq
28  2023 [Acquired alpha-thalassemia in an 86-year-old patient with myelodysplastic syndrome]. ATMDS
29  2023 [Recent advances in the treatment of myelodysplastic syndromes (MDS)]. ---
30  2022 A Deep Learning Model for the Automatic Recognition of Aplastic Anemia, Myelodysplastic Syndromes, and Acute Myeloid Leukemia Based on Bone Marrow Smear. AA, AML, ASH, AUC, CI, CNN, NPV, PPV
31  2022 A machine learning model of response to hypomethylating agents in myelodysplastic syndromes. AUROC, HMA
32  2022 A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry. LR, RS
33  2022 A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. AML, CMML, MAPK, MPN
34  2022 A Novel Multicolor Flow Cytometry Scoring System for the Diagnosis and Prognostic Stratification of Myelodysplastic Syndromes. FCSS
35  2022 A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation. IPSS-R, MDS-RS, OS, WHO
36  2022 A Pathogenic NRAS c.38 G>A (p.G13D) Mutation in RARA Translocation-negative Acute Promyelocytic-like Leukemia with Concomitant Myelodysplastic Syndrome. APL, RARA
37  2022 A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. 2-HG, AEs, AML, CR, IDH1
38  2022 A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. AML, DNMTi, JAK
39  2022 A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. AML, CMML, LIC
40  2022 A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. HI, HMA, IWG, OS, R/R, TI
41  2022 A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors. AML, GVHD, HCT, NK
42  2022 A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. AML, CTCL, NHL, ORR, RP2D
43  2022 A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm. BRBs, HMAs, MDS/MPN, PBMCs
44  2022 A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. AZA, IDA, LEN, VPA
45  2022 A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. AML, CMML
46  2022 A Rare Case of Ankylosing Spondylitis Coexisting with Relapsing Polychondritis, Antiphospholipid Syndrome, and Myelodysplastic Syndrome. APS, AS, RP
47  2022 A research review of experimental animal models with myelodysplastic syndrome. ---
48  2022 A Systematic Literature Review of the Relationship between Serum Ferritin and Outcomes in Myelodysplastic Syndromes. SF, SLR
49  2022 A Systematic Review of the Role of Runt-Related Transcription Factor 1 (RUNX1) in the Pathogenesis of Hematological Malignancies in Patients With Inherited Bone Marrow Failure Syndromes. AML, CMMT, CXXC4, FPD, GCSF3R, IBMFS, iPSCs, MeSH, WES
50  2022 A treatment-refractory aggressive MDS-MLD with multiple highly complex chromosome 5 intrachromosomal rearrangements: a case report. ---
51  2022 ABAT gene expression associated with the sensitivity of hypomethylating agents in myelodysplastic syndrome through CXCR4/mTOR signaling. GC-MS, HMAs
52  2022 Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia. AML, DMRs, MSCs
53  2022 Abnormal platelet immunophenotypes and percentage of giant platelets in myelodysplastic syndrome: A pilot study. FSC
54  2022 Abstracts of Presentations at the Association of Clinical Scientists 143rd Meeting Louisville, KY May 11-14,2022. ACS, AD, AH, AI, ALBU, ALD, AML, ARDS, ASAP, CDC, CNV, CSF, ctDNA, CyTOF, DESI, DFS, DHT, ECHA, EM, ER, FLVs, GBM, HCC, IGFBP-3, IGFBP7, IGFs, IHC, IND, LA, LOD, MAF, mAH, MALDI-TOF, MARS, MPN, MRM, NGS, NP, NPH, OS, p-Tau, PCR, PEEP, PG, PR, PSRBCT, Q-GRFT, RA, ROTEM, SEER, SLN, t-Tau, TB, TEG, TEM, TGF-beta, TNF, ToF-SIMS, UChicago, VET, VTM, YAP1, ZIKV
55  2022 Acquired and hereditary bone marrow failure: A mitochondrial perspective. BMFS, HSC
56  2022 Acquired spherocytosis in the setting of myelodysplasia. HS, NGS, RBC
57  2022 Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. AML, IRAK4
58  2022 Adaptation of Serious Illness Care Program to be Delivered via Telehealth for Older Patients with Hematologic Malignancy. ACP, AML, EOL, SICP
59  2022 Advance care planning in older patients with acute myeloid leukemia and myelodysplastic syndromes. ACP, AML, EOL, MOLST
60  2022 Adverse events caused by cord blood infusion in Japan during a 5-year period. CBBs, CTCAE, ISBT
61  2022 Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis. AML, AO, TCDD, US
62  2022 Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes. AML, KMT2A-PTD, NGS
63  2022 Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study. allo-HSCT, DEC, GRFS, GVHD, OS, PFS
64  2022 Allogeneic stem cell transplantation for patients with myelodysplastic syndromes. allo-HSCT, RIC
65  2022 Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behcet's disease: Case report and the review of literature. allo-SCT, BD, TNF
66  2022 Allogeneic transplantation for advanced acute leukemia. HCT
67  2022 Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms. CSF3R, ESE
68  2022 AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax. AML, TKI
69  2022 Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways. AML, AZA, HMA
70  2022 Antisenescence effect of REAC biomodulation to counteract the evolution of myelodysplastic syndrome. AML, BMSCs, REAC, TO-RGN
71  2022 Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine. AML, DC, HMAs
72  2022 Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS). CMML, IPSS, WHO
73  2022 Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia. AML, CHIP, CRP, CVD, hs-CRP
74  2022 Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer. AML, G-CSF
75  2022 Association between transfusion status and clinical and economic outcomes in patients with myelodysplastic syndromes from the physicians' perspective. AML, ER, TD, TI, TS
76  2022 Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia. AA, ITP
77  2022 Association of systemic inflammatory and autoimmune manifestations with myelodysplastic syndromes: A systematic review and meta-analysis. CI, SIAMs
78  2022 ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial. DA
79  2022 Auer rods and faggot cells: A review of the history, significance and mimics of two morphological curiosities of enduring relevance. AML, MDS/MPN
80  2022 Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications. AD
81  2022 Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis. allo-HSCT, AML, BM, CI, DLI, GVHD, OS
82  2022 Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors. AML, AZA, CR, DLI, EFS, HSCT, ORR, OS
83  2022 Azacitidine Monotherapy in Patients With Treatment-Naive Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. AEs, AZA, CR, DOR, OS, PR, RCTs, TTR
84  2022 Beyond the routine CBC: machine learning and statistical analyses identify research CBC parameter associations with myelodysplastic syndromes and specific underlying pathogenic variants. AUC, CBC, ROC
85  2022 Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy. BGN, BM, BMBs, ECM, sAML
86  2022 Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen. AML, MPN, MS
87  2022 BMT for Myelodysplastic Syndrome: When and Where and How. allo-BMT, EMAs, ESAs, HMAs, HR, IMiDs, IPSS, IPSS-R, LR, MDAPSS, TRM, WPSS
88  2022 Bone marrow CD3+ CD56+ regulatory T lymphocytes (TR3 -56 cells) are inversely associated with activation and expansion of bone marrow cytotoxic T cells in IPSS-R very-low/low risk MDS patients. BM, CTL
89  2022 Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. BM, BPDCN, CH, CMML
90  2022 Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome. MF
91  2022 Bone marrow fibrosis impact on response to azacitidine in myelodysplastic syndromes. ---
92  2022 Bone marrow free immune checkpoints as a potential biomarker for differential diagnosis of acquired bone marrow failures. AA, ICUS, IST
93  2022 Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes. AML, HSCs, IME, MDSCs
94  2022 Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes. AML, BMSCs, NK, TIGIT
95  2022 Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes. BMME, ECM, GAG, HA, HR, HSPCs, LR, MSCs
96  2022 Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia. AML, DKO, IL-6R
97  2022 CAISC: A software to integrate copy number variations and single nucleotide mutations for genetic heterogeneity profiling and subclone detection by single-cell RNA sequencing. CAISC, CNVs, scRNA-seq, SNVs
98  2022 Case Report: A novel WRN mutation in Werner syndrome patient with diabetic foot disease and myelodysplastic syndrome. ---
99  2022 Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome. MM
100  2022 Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease. AIS